Four modafinil doses for adults with ADHD
About this title
Read the official source — NCT00315276This study evaluated the safety and effectiveness of Modafinil for people with ADHD.
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Modafinil for people with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 17 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 370
- Sponsor
- Cephalon
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00315276
- Official title
Show the full official title
A 9-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With Attention Deficit/Hyperactivity Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Little Rock · Lafayette · Northridge
15 more locations
- Rolling Hills Estates
- San Diego
- Orlando
- Chicago
- Lexington
- Lutherville
- Cambridge
- Rochester
- Clementon
- New York
- Portland
- Philadelphia
- Charleston
- Memphis
- Woodstock
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Modafinil for people with ADHD.
Who is behind this study?
The study sponsor is Cephalon.
Did this study involve medication?
Yes. The study involved medication, including Modafinil.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
